What's Making News

March 1, 2018 - 2:13am

As a proud member of Neurological Health Charities Canada (NHCC), DMRF Canada is pleased to present an opinion piece in the Globe and Mail that speaks to the urgent need for additional research funding and more supports provided to individuals dealing with neurological conditions in Canada. Read the article here.

February 27, 2018 - 9:37am

Cervical dystonia is a focal dystonia that affects the head and neck. Cervical dystonia produces excessive muscle contractions in the neck. These muscle contractions cause involuntary, repetitive movements and awkward positions of the head, neck, and sometimes shoulders.

Cervical dystonia is sometimes referred to as spasmodic torticollis.

Cervical dystonia may cause:

February 26, 2018 - 4:25pm

The Dystonia Medical Research Foundation (DMRF) Canada, in partnership with Allergan Canada, is pleased to announce the selection of the candidate for the first-ever Clinical Fellowship for Movement Disorders, with a specialty in dystonia.  Please click here to learn more.

February 26, 2018 - 10:25am

Details of the study and eligibility details are available here. Canadian patients are welcome to participate in the study if eligible. The exception for international participants is that while some travel expenses are covered once participants have been enrolled in the study, only certain expenses within the United States can be covered. 

February 4, 2018 - 6:44am

Approval is based on the first large-scale neurotoxin trial to demonstrate meaningful functional improvement in pediatric lower limb spasticity

The Ipsen Biopharmaceuticals Canada Inc., the Canadian affiliate of Ipsen (EURONEXT PARIS: IPN) (ADR: IPSEY) today announced that Health Canada has approved DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients two years of age and older.

Click here for the press release.